ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

PHASE4CompletedINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2017

Study Completion Date

January 31, 2018

Conditions
Hematopoietic Stem Cell TransplantationAntithymocyte GlobulinViral Infection
Interventions
DRUG

ATG

ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Southern Medical University, China

OTHER

collaborator

Guangzhou General Hospital of Guangzhou Military Command

OTHER

collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Xiangya Hospital

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT01883180 - ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis | Biotech Hunter | Biotech Hunter